Ligand Trounces Q2 Estimates by Helping Companies Make COVID-19 Drug Remdesivir
Ligand Pharmaceuticals' (NASDAQ: LGND) big slide in March was only short-lived. Its shares have rebounded nicely over the last several months and came into this week up 12% year to date.
The biotech announced its second-quarter results before the market opened on Monday. Here's what you need to know about Ligand's Q2 results.
Image source: Getty Images.
Source Fool.com
